Login to Your Account

Putting the Others 'Duchenne'? Sarepta's Phase IIb Data Dazzle

By Randy Osborne
BioWorld Today Contributing Writer

Thursday, October 4, 2012
Neither the smallish trial size nor two extra-sick patients in the lower-dose arm could dampen Wall Street's enthusiasm for eye-opening Phase IIb results disclosed by Sarepta Therapeutics Inc. in Duchenne muscular dystrophy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription